MX2021000515A - Uso de profarmacos de riluzol para tratar enfermedad de alzheimer. - Google Patents
Uso de profarmacos de riluzol para tratar enfermedad de alzheimer.Info
- Publication number
- MX2021000515A MX2021000515A MX2021000515A MX2021000515A MX2021000515A MX 2021000515 A MX2021000515 A MX 2021000515A MX 2021000515 A MX2021000515 A MX 2021000515A MX 2021000515 A MX2021000515 A MX 2021000515A MX 2021000515 A MX2021000515 A MX 2021000515A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- treat alzheimer
- riluzole
- riluzole prodrugs
- prodrugs
- Prior art date
Links
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 title abstract 3
- 239000000651 prodrug Substances 0.000 title abstract 3
- 229940002612 prodrug Drugs 0.000 title abstract 3
- 229960004181 riluzole Drugs 0.000 title abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- YBZSGIWIPOUSHY-UHFFFAOYSA-N troriluzole Chemical compound NCC(=O)NCC(N(CC(NC=1SC2=C(N=1)C=CC(=C2)OC(F)(F)F)=O)C)=O YBZSGIWIPOUSHY-UHFFFAOYSA-N 0.000 abstract 1
- 229940121629 troriluzole Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701814P | 2018-07-22 | 2018-07-22 | |
| PCT/US2019/042718 WO2020023324A1 (en) | 2018-07-22 | 2019-07-20 | Use of riluzole prodrugs to treat alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021000515A true MX2021000515A (es) | 2021-06-08 |
Family
ID=69181140
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000515A MX2021000515A (es) | 2018-07-22 | 2019-07-20 | Uso de profarmacos de riluzol para tratar enfermedad de alzheimer. |
| MX2024010655A MX2024010655A (es) | 2018-07-22 | 2021-01-14 | Uso de profarmacos de riluzol para tratar enfermedad de alzheimer. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024010655A MX2024010655A (es) | 2018-07-22 | 2021-01-14 | Uso de profarmacos de riluzol para tratar enfermedad de alzheimer. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12161633B2 (https=) |
| EP (1) | EP3823616A4 (https=) |
| JP (2) | JP2021530543A (https=) |
| KR (1) | KR20210034621A (https=) |
| CN (1) | CN112469408A (https=) |
| AU (1) | AU2019310013B2 (https=) |
| BR (1) | BR112021000768A2 (https=) |
| CA (1) | CA3107215A1 (https=) |
| EA (1) | EA202190308A1 (https=) |
| IL (1) | IL280177B2 (https=) |
| MX (2) | MX2021000515A (https=) |
| NZ (1) | NZ772009A (https=) |
| PH (1) | PH12021550043A1 (https=) |
| SG (1) | SG11202100385YA (https=) |
| WO (1) | WO2020023324A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7805969B2 (ja) * | 2020-06-24 | 2026-01-26 | バイオヘイブン・セラピューティクス・リミテッド | 強迫性障害を治療するための組成物及び方法 |
| US20240016783A1 (en) * | 2020-10-05 | 2024-01-18 | Icahn School Of Medicine At Mount Sinai | Riluzole for the treatment of alzheimer's disease |
| EP4277624B1 (en) * | 2021-01-18 | 2026-01-14 | Biohaven Therapeutics Ltd. | Troriluzole for use in the treatment of alzheimer's disease of mild severity |
| AU2022222778A1 (en) * | 2021-02-22 | 2023-08-31 | Yale University | Targeted bifunctional degraders and methods using same |
| CN114344297B (zh) * | 2022-03-01 | 2024-05-14 | 暨南大学 | 利鲁唑在治疗少精症中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004501875A (ja) * | 2000-06-14 | 2004-01-22 | メダレックス，インコーポレイティド | トリペプチドプロドラッグ化合物 |
| JP2008518935A (ja) * | 2004-11-01 | 2008-06-05 | セオ ホン ユー | 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物 |
| FR2957077B1 (fr) * | 2010-03-02 | 2012-04-13 | Univ Dauvergne Clermont I | Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux |
| CA2933464A1 (en) | 2013-12-09 | 2015-06-18 | Thomas Jefferson University | Use of abc drug efflux inhibitors in combination with anti-neurodegenerative drugs in the treatment of neurodegenerative disorders |
| KR102462638B1 (ko) * | 2014-11-26 | 2022-11-03 | 메디시노바, 인크. | 이부딜라스트와 릴루졸의 배합물 및 이의 사용방법 |
| WO2016140879A1 (en) * | 2015-03-03 | 2016-09-09 | Biohaven Pharmaceutical Holding Company Ltd. | Riluzole prodrugs and their use |
| LT3458053T (lt) * | 2016-05-20 | 2022-02-25 | Biohaven Pharmaceutical Holding Company Ltd. | Riluzolo, rilizolo provaistų arba riluzolo analogų panaudojimas kartu su imunoterapijomis vėžio formų gydymui |
| WO2018031707A1 (en) | 2016-08-10 | 2018-02-15 | Biohaven Pharmaceutical Holding Company Ltd. | Acyl benzo[d]thiazol-2-amine and their methods of use |
| TW202000205A (zh) * | 2018-02-21 | 2020-01-01 | 美商Ａｉ治療公司 | 使用阿吡莫德與麩胺酸性劑的組合治療 |
| EP4277624B1 (en) * | 2021-01-18 | 2026-01-14 | Biohaven Therapeutics Ltd. | Troriluzole for use in the treatment of alzheimer's disease of mild severity |
-
2019
- 2019-07-20 MX MX2021000515A patent/MX2021000515A/es unknown
- 2019-07-20 EP EP19841953.3A patent/EP3823616A4/en active Pending
- 2019-07-20 EA EA202190308A patent/EA202190308A1/ru unknown
- 2019-07-20 CN CN201980048687.7A patent/CN112469408A/zh active Pending
- 2019-07-20 WO PCT/US2019/042718 patent/WO2020023324A1/en not_active Ceased
- 2019-07-20 IL IL280177A patent/IL280177B2/en unknown
- 2019-07-20 CA CA3107215A patent/CA3107215A1/en active Pending
- 2019-07-20 NZ NZ772009A patent/NZ772009A/en unknown
- 2019-07-20 SG SG11202100385YA patent/SG11202100385YA/en unknown
- 2019-07-20 US US17/261,057 patent/US12161633B2/en active Active
- 2019-07-20 KR KR1020217004639A patent/KR20210034621A/ko not_active Ceased
- 2019-07-20 AU AU2019310013A patent/AU2019310013B2/en active Active
- 2019-07-20 JP JP2021503571A patent/JP2021530543A/ja active Pending
- 2019-07-20 BR BR112021000768-7A patent/BR112021000768A2/pt unknown
-
2021
- 2021-01-07 PH PH12021550043A patent/PH12021550043A1/en unknown
- 2021-01-14 MX MX2024010655A patent/MX2024010655A/es unknown
-
2025
- 2025-02-21 JP JP2025026643A patent/JP2025093952A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3823616A1 (en) | 2021-05-26 |
| IL280177B1 (en) | 2024-09-01 |
| JP2021530543A (ja) | 2021-11-11 |
| US20210290599A1 (en) | 2021-09-23 |
| MX2024010655A (es) | 2024-09-11 |
| NZ772009A (en) | 2026-02-27 |
| AU2019310013B2 (en) | 2025-01-02 |
| BR112021000768A2 (pt) | 2021-05-11 |
| PH12021550043A1 (en) | 2021-09-20 |
| EP3823616A4 (en) | 2022-05-04 |
| WO2020023324A1 (en) | 2020-01-30 |
| IL280177A (en) | 2021-03-01 |
| KR20210034621A (ko) | 2021-03-30 |
| US12161633B2 (en) | 2024-12-10 |
| AU2019310013A1 (en) | 2021-02-11 |
| IL280177B2 (en) | 2025-01-01 |
| CN112469408A (zh) | 2021-03-09 |
| JP2025093952A (ja) | 2025-06-24 |
| CA3107215A1 (en) | 2020-01-30 |
| EA202190308A1 (ru) | 2021-05-19 |
| SG11202100385YA (en) | 2021-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010655A (es) | Uso de profarmacos de riluzol para tratar enfermedad de alzheimer. | |
| ZA202006190B (en) | Rimegepant for cgrp related disorders | |
| ZA202002626B (en) | Use of riluzole prodrugs to treat ataxias | |
| PH12018502634A1 (en) | Topical compositions of apremilast | |
| PH12018500087A1 (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors | |
| JOP20190146A1 (ar) | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد | |
| PH12017500746B1 (en) | Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease | |
| PH12021550443A1 (en) | Pyridazinones and methods of use thereof | |
| PH12017500444A1 (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
| MX2020002884A (es) | Método y composición neuroprotectora mejorada para tratar afecciones neurológicas. | |
| MY207469A (en) | Therapeutic compounds | |
| PH12021550671A1 (en) | Prodrugs of cgrp antagonists | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| MX2024007642A (es) | Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades. | |
| MX389282B (es) | Composiciones y métodos para tratar sinucleinopatías. | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
| MX2020013692A (es) | Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma. | |
| PH12018500469A1 (en) | Sulfonamide compounds as voltage-gated sodium channel modulators | |
| MX2016008968A (es) | Compuestos organicos. | |
| MX2019004179A (es) | Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer. | |
| EP4620940A3 (en) | Synthesis of (+)-cannabinoids and their therapeutic effects | |
| MX2019003720A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| EA202091162A1 (ru) | Применение пролекарств рилузола для лечения атаксии | |
| HK40041745A (en) | Use of riluzole prodrugs to treat alzheimer's disease |